EVENTS | VIEW CALENDAR
Parion and Kainos sign development agreement
DURHAM, N.C.—Parion Sciences Inc. and Korean pharma Kainos Medicines Inc. recently announced they reached an agreement to co-develop Parion's proprietary epithelial sodium channel blocker, P-552, for the treatment of dry mouth associated with primary Sjogren's syndrome.
Under the agreement, the companies will collaborate on the clinical development of P-552. Kainos will provide funding to help advance the program through the end of Phase II clinical testing, supplying up to $25 million upon completion of all milestones. Parion will be responsible for the oversight of the clinical development program while Kainos will provide CMC (chemistry, manufacturing and controls) expertise. Upon the successful completion of the Phase II program, Parion and Kainos will determine the Phase III clinical development and commercialization of P-552.
"Sjogren's syndrome patients are seeking effective relief of their dry mouth. By combining the talents and expertise of two proven development teams, we believe we can accelerate the clinical development of P-552 to effectively address this unmet need," says M. Ross Johnson, Parion's CEO. "This partnership represents the second application of our portfolio of sodium channel blockers as we continue to expand Parion's unique technology and novel compound library into other diseases requiring mucosal hydration."
In a Phase I/II clinical study completed in April 2008, P-552 was found to be safe and tolerable in subjects with primary Sjogren's syndrome. The study demonstrated promising results in several key quality of life parameters including mouth dryness, mouth comfort and ability to sleep, as assessed by Visual Analogue Scale (VAS).
"I am very pleased that Kainos and Parion will be working together on the development of P-552," says M.C. Kang, Kainos' CEO. "Strategically, each partner brings its complementary expertise to the collaboration. This will provide a comprehensive and complete development program for P-552 and support the business strategy of Kainos Medicines." DDN